Newsroom Bayer

January
27,
2023
| 12:59 PM Europe/Amsterdam
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel alone, with
January
24,
2023
| 13:59 PM Europe/Amsterdam
Jeffrey Hatfield becomes Chairman of the Board of Directors at Vividion Therapeutics
January
23,
2023
| 08:29 AM Europe/Amsterdam
Ultravist™-300, -370 receives green light for indication extension for use in contrast-enhanced mammography (CEM) in a European Workshare Procedure  / CEM is emerging modality combining digital mammography with the administration of a contrast agent
January
19,
2023
| 11:59 AM Europe/Amsterdam
Oerth’s unique PROTAC protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the combination of Oerth Bio’s specialized expertise designing PROTAC
January
18,
2023
| 08:29 AM Europe/Amsterdam
Acquisition is part of Bayer’s innovation strategy in radiology / Blackford Analysis provides cutting-edge radiology AI (artificial intelligence) platform technology / Following closing of the acquisition, Blackford Analysis to become part of
January
11,
2023
| 16:59 PM Europe/Amsterdam
Bayer to speed up its in-silico research and development with Google Cloud’s high-speed processors / Collaboration aims to enable Bayer to run large quantum chemistry calculations at scale using Google Tensorflow Processing
January
10,
2023
| 14:59 PM Europe/Amsterdam
Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells
January
10,
2023
| 13:59 PM Europe/Amsterdam
Strong market uptake of Nubeqa™ and Kerendia™ / Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention  / High-value late-stage development portfolio  / Positive study outcomes from
January
09,
2023
| 13:59 PM Europe/Amsterdam
Research Triangle Park, N.C. (January 9, 2023) - Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option
January
09,
2023
| 08:45 AM Europe/Amsterdam
-- Certification expands Viralgen's capacity threefold and positions the company as a world-leading CDMO ---- New facility operates single-use bioreactors from 50 to 2,000 liters and manufactures research, clinical and commercial grade rAAV vectors
December
20,
2022
| 19:09 PM Europe/Amsterdam
Research Triangle Park, N.C. (December 20, 2022) - Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA’s approval of a new adeno-associated virus (AAV) gene

Sign up for our Newsletter

We will keep you informed about the latest news.